HMNC Brain Health
Annet Glas, PhD MBA, is an accomplished professional with extensive experience in clinical development and neuroscience research. Currently serving as Associate Director of Clinical Development at HMNC Brain Health since December 2021, Annet oversees the Cortibon program and manages clinical study planning across phases I and II, along with vendor management and market analysis. Prior roles include positions at McKinsey & Company, where strategic insights were provided to pharmaceutical and agricultural clients, and a PhD candidacy at the Max Planck Institute for Biological Intelligence, resulting in three peer-reviewed publications. Annet holds an MBA from the Quantic School of Business and Technology, a PhD in Neuroscience from the Graduate School of Systemic Neurosciences at LMU Munich, and multiple degrees in the field, including a Master of Science and a Bachelor of Science in Medical Biology from Radboud University.
This person is not in any offices
HMNC Brain Health
HMNC Brain Health develops patented genetic tests and combines those with innovative exclusively in-licensed medications, resulting in precise therapies for depression and other neuropsychiatric disorders.Founded in 2010, the privately held biotech company combines the development of machine learning-enabled companion diagnostics with specifictherapeutics to personalize the treatment of neuropsychiatric disorders with a focus on depression. The ultimate goal is to improve the lives of patients by developing highly disruptive solutions for their high unmet medical needs. HMNC Brain Health strives to reduce not only the immense individual burden but also the societal impact of these diseases.